2024
Leveraging real-world data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the management of pediatric hospital–acquired pneumonia
Blumenstock J, Faerber J, Menon M, Lawler R, Downes K, Kratz E, Erickson K, Haltzman-Cassenti B, Yildirim I, Hussaini L, Elmontser M, Sederdahl B, Hahn A, Thomson J, Newland J, Terrill C, Bradley J, Zachariah P, Younus M, Mo J, Wible M, Tawadrous M, Fisher B. Leveraging real-world data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the management of pediatric hospital–acquired pneumonia. American Journal Of Epidemiology 2024, 194: 1426-1435. PMID: 39108170, DOI: 10.1093/aje/kwae251.Peer-Reviewed Original ResearchIncidence rate ratiosPediatric Health Information SystemHospital-acquired pneumoniaMedical recordsHealth information systemsPoisson regression modelsBetween-group differencesStudy combined dataEffects of medicationAdministrative claimsRate ratiosClinical improvementSecondary outcomesBetween-groupEffect of piperacillin-tazobactamComparative riskReal World DataHospital acquired pneumoniaRegression modelsTreating hospital-acquired pneumoniaOff-label settingCIPediatric institutionControlled studiesPiperacillin-tazobactam
2023
The impact of COVID-19 on microbiological profile and antibiotic consumption in ICU: a retrospective study in an infectious disease hospital in Brazil
de França Diniz Rocha V, da Silva E, Azevedo J, Ribeiro M, Reis M, Barros T, Reis J. The impact of COVID-19 on microbiological profile and antibiotic consumption in ICU: a retrospective study in an infectious disease hospital in Brazil. The Brazilian Journal Of Infectious Diseases 2023, 28: 103705. PMID: 38065221, PMCID: PMC10764251, DOI: 10.1016/j.bjid.2023.103705.Peer-Reviewed Original ResearchConceptsIntensive care unitInfectious Diseases HospitalAntimicrobial resistanceMicrobiological profileCandida sppRetrospective studyTracheal secretionsCarbapenem-resistant A. baumanniiConsequences of antimicrobial resistanceIntensive care unit patient-daysImpact of antimicrobial resistanceMultidrug-resistant Enterococcus faeciumCharacteristics of patientsConsumption of ceftriaxoneConsumption of antibioticsPiperacillin-tazobactamUnique characteristics of patientsA. baumanniiAcinetobacter baumanniiAntibiotic consumptionEnterobacter speciesIncidence densityESKAPE groupClinical culturesKlebsiella pneumoniae
2022
Chronic cholecystitis from Raoultella planticola infection associated with adenomyomatous hyperplasia
Doherty G, Kreinces J, Souza F, Kim D. Chronic cholecystitis from Raoultella planticola infection associated with adenomyomatous hyperplasia. Journal Of Surgical Case Reports 2022, 2022: rjac529. PMID: 36452290, PMCID: PMC9704786, DOI: 10.1093/jscr/rjac529.Peer-Reviewed Original ResearchAdenomyomatous hyperplasiaChronic cholecystitisBlood culturesEvidence of cholecystitisLower abdominal painNegative rod bacteremiaHistory of immunosuppressionSignificant risk factorsBiliary ductal dilatationMagnetic resonance cholangiopancreatographyPositive blood culturesUnderlying malignancyAbdominal painBile culturesDuctal dilatationDiabetes mellitusLaparoscopic cholecystectomyPiperacillin-tazobactamResonance cholangiopancreatographyRisk factorsCholecystitisComputed tomographyHyperplasiaInfectionPatientsAssociation of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Medicine 2022, 48: 1144-1155. PMID: 35833959, PMCID: PMC9463324, DOI: 10.1007/s00134-022-06811-0.Peer-Reviewed Original ResearchConceptsPiperacillin-tazobactamKidney biomarkersCystatin CAcute kidney injury riskProspective cohort studyCystatin C concentrationCystatin C measurementKidney function biomarkersCreatinine secretionAntibiotic initiationCohort studyProspective cohortIll adultsClinical outcomesAssociation of vancomycinAntibiotic treatmentTubular secretionCreatinine concentrationTreatment weightingResultsThe studyTrue injuryHigh incidenceCreatinineDay 14Early changes
2018
Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients
Pettigrew MM, Gent JF, Kong Y, Halpin AL, Pineles L, Harris AD, Johnson JK. Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients. Clinical Infectious Diseases 2018, 69: 604-613. PMID: 30383203, PMCID: PMC6669284, DOI: 10.1093/cid/ciy936.Peer-Reviewed Original ResearchConceptsCarbapenem-resistant Pseudomonas aeruginosaIntensive care unit patientsCare unit patientsPiperacillin-tazobactamUnit patientsICU patientsMarker of riskMaryland Medical CenterRisk of colonizationRibosomal RNA gene sequencingRNA gene sequencingAdmission swabCRPA infectionPseudomonas aeruginosaICU admissionPatient characteristicsMicrobiota disruptionMedical CenterGastrointestinal tractAdditional swabsAntimicrobial exposureLower riskEvaluated associationsPatientsProtective role
2002
Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and β-Lactams against Gram-Positive Clinical Isolates
Bassetti M, Dembry L, Farrel P, Callan D, Andriole V. Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and β-Lactams against Gram-Positive Clinical Isolates. Antimicrobial Agents And Chemotherapy 2002, 46: 234-238. PMID: 11751142, PMCID: PMC126992, DOI: 10.1128/aac.46.1.234-238.2002.Peer-Reviewed Original ResearchConceptsBMS-284756Clinical isolatesGram-positive clinical isolatesResistant coagulase-negative staphylococciBeta-hemolytic streptococciAmoxicillin-clavulanic acidPositive clinical isolatesResistant Staphylococcus aureusCoagulase-negative staphylococciPiperacillin-tazobactamStreptococcus viridansStreptococcus pneumoniaeStaphylococcus aureusΒ-lactamsActive agentsIsolatesCeftriaxoneAntibacterial activityImipenemMoxifloxacinPneumoniaeViridansFluoroquinolones
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply